TriangleTrastuzumab Deruxtecan (NCT06533826)
Trastuzumab Deruxtecan trial for Breast Cancer (NCT06533826). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable or metastatic breast cancer that has always been HER2-low or HER2-zero. Prior-treatment requirements differ by group and hormone-receptor status.
The idea: trastuzumab deruxtecan targets HER2; datopotamab deruxtecan targets TROP2. Both carry a DNA-damaging drug. Assignment is random, with a switch after progression; some patients enter after the first drug. Infusions occur every three weeks. Researchers measure responses to each sequence. Tumor biopsies are required when safely accessible.
This phase 2 study plans 357 patients. Ana Garrido-Castro leads at Dana-Farber in Boston; ten US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.